ChatGPT question: How does Leronlimab turn cold tumors hot for check point inhibitors to work?
Leronlimab (also known as PRO 140) is a humanized monoclonal antibody that targets CCR5, a receptor involved in immune cell trafficking, inflammation, and tumor metastasis. Its proposed mechanism for converting “cold” tumors into “hot” tumors—thus enhancing the effectiveness of immune checkpoint inhibitors—centers on modulating the tumor microenvironment (TME). Here’s how it works:
⸻
???? Cold vs. Hot Tumors
• Cold tumors: Immunologically “silent” — they have few T cells, low inflammation, and are often resistant to immune checkpoint inhibitors like PD-1/PD-L1 blockers.
• Hot tumors: Infiltrated by immune cells, particularly cytotoxic T cells (CD8+), making them more responsive to immunotherapy.
⸻
???? How Leronlimab Helps Turn Tumors Hot
1. CCR5 Blockade Reduces Immune Suppression
• Many myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) express CCR5.
• These cells promote an immune-suppressive environment, shielding tumors from immune attack.
• By blocking CCR5, Leronlimab:
• Reduces recruitment of these suppressive cells.
• Shifts macrophage polarization from M2 (pro-tumor) to M1 (anti-tumor).
2. Promotes T Cell Infiltration
• Leronlimab can increase infiltration of CD8+ T cells into the tumor by:
• Altering chemokine gradients.
• Reducing barriers to T cell entry (like fibrotic stroma and suppressive cytokines).
3. Decreases Treg Activity
• Regulatory T cells (Tregs) also use CCR5 to home to tumors.
• Blocking CCR5 may reduce Treg trafficking, further relieving immune suppression.
4. Enhances Response to Checkpoint Inhibitors
• Once the TME is more immunogenic (“hot”), checkpoint inhibitors like anti-PD-1 or anti-CTLA-4 can be more effective.
• Leronlimab may synergize with these drugs by “priming” the tumor for immune attack.
⸻
???? Clinical and Preclinical Evidence
• Preclinical studies show Leronlimab increases T cell infiltration and decreases metastasis in models of breast and prostate cancer.
• Early clinical trials (e.g., in triple-negative breast cancer and colon cancer) have suggested potential immune activation and reduction in tumor burden when Leronlimab is used alongside checkpoint inhibitors.
⸻
Summary
Leronlimab turns tumors “hot” by blocking CCR5, which reshapes the immune landscape of the tumor:
• Decreasing suppressive cells (TAMs, MDSCs, Tregs),
• Promoting effector T cell infiltration,
• Making the tumor responsive to immunotherapy.
This mechanism supports its use as a complementary agent in immuno-oncology, especially in tumors that are initially resistant to immune checkpoint blockade.
Leronlimab (also known as PRO 140) is a humanized monoclonal antibody that targets CCR5, a receptor involved in immune cell trafficking, inflammation, and tumor metastasis. Its proposed mechanism for converting “cold” tumors into “hot” tumors—thus enhancing the effectiveness of immune checkpoint inhibitors—centers on modulating the tumor microenvironment (TME). Here’s how it works:
⸻
???? Cold vs. Hot Tumors
• Cold tumors: Immunologically “silent” — they have few T cells, low inflammation, and are often resistant to immune checkpoint inhibitors like PD-1/PD-L1 blockers.
• Hot tumors: Infiltrated by immune cells, particularly cytotoxic T cells (CD8+), making them more responsive to immunotherapy.
⸻
???? How Leronlimab Helps Turn Tumors Hot
1. CCR5 Blockade Reduces Immune Suppression
• Many myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) express CCR5.
• These cells promote an immune-suppressive environment, shielding tumors from immune attack.
• By blocking CCR5, Leronlimab:
• Reduces recruitment of these suppressive cells.
• Shifts macrophage polarization from M2 (pro-tumor) to M1 (anti-tumor).
2. Promotes T Cell Infiltration
• Leronlimab can increase infiltration of CD8+ T cells into the tumor by:
• Altering chemokine gradients.
• Reducing barriers to T cell entry (like fibrotic stroma and suppressive cytokines).
3. Decreases Treg Activity
• Regulatory T cells (Tregs) also use CCR5 to home to tumors.
• Blocking CCR5 may reduce Treg trafficking, further relieving immune suppression.
4. Enhances Response to Checkpoint Inhibitors
• Once the TME is more immunogenic (“hot”), checkpoint inhibitors like anti-PD-1 or anti-CTLA-4 can be more effective.
• Leronlimab may synergize with these drugs by “priming” the tumor for immune attack.
⸻
???? Clinical and Preclinical Evidence
• Preclinical studies show Leronlimab increases T cell infiltration and decreases metastasis in models of breast and prostate cancer.
• Early clinical trials (e.g., in triple-negative breast cancer and colon cancer) have suggested potential immune activation and reduction in tumor burden when Leronlimab is used alongside checkpoint inhibitors.
⸻
Summary
Leronlimab turns tumors “hot” by blocking CCR5, which reshapes the immune landscape of the tumor:
• Decreasing suppressive cells (TAMs, MDSCs, Tregs),
• Promoting effector T cell infiltration,
• Making the tumor responsive to immunotherapy.
This mechanism supports its use as a complementary agent in immuno-oncology, especially in tumors that are initially resistant to immune checkpoint blockade.
10
